RxDoctor Payments Data

Anil Paramesh, MD

Transplant Surgery · Metairie, LANPI 1255390738

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $16,900 of the $20,508 with a category attached, or 82.4%. Davol Inc. accounts for 82.4% of it on its own, with 25 other manufacturers making up the rest.

$20,508in general payments, 2019–2025

Across 80 payments — averaging $256.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Davol Inc.$17K
  • Intuitive Surgical$1K
  • United Therapeutics Corporation$388
  • Amgen$274
  • Gilead$265
  • Veloxis Pharmaceuticals, Inc.$240
  • plus $1K from 20 others
$60,162in research payments, 2019–2025

Across 40 payments — averaging $1504.06 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • CSL Behring$34K
  • E.r. Squibb & Sons, L.L.C.$26K

What the payments were for

  • Consulting fees$16,90082%
  • Travel & lodging$420%
  • Food & beverage$2,42912%
  • Education$1,1376%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few transplant surgery providers in Louisianato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$70,377
Medicare patients
89
Services billed
368

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VeltassaPatiromer Calcium Sorbitex20$19,337
Valganciclovir Hcl79$15,866
Atovaquone21$11,055
Tacrolimus28$8,691
Mycophenolic AcidMycophenolate Sodium23$4,946
Fluconazole53$1,452
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim189$637
Famotidine82$524
Nystatin18$504
Prednisone81$368
Carvedilol15$101
Pantoprazole Sodium15$51
Amlodipine Besylate18$44
Furosemide12$14

Paid to pharmacies, not to this prescriber.

Other transplant surgery in Metairie

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →